Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

A Study of Buntanetap in Participants With PD

NCT07284784
recruitingphase_3

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT06709014
completedphase_2

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

NCT05686044
completedphase_3

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989

Clinical Trials (4)

Showing 4 of 4 trials
NCT07284784Phase 2

A Study of Buntanetap in Participants With PD

Recruiting
NCT06709014Phase 3

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
NCT05686044Phase 2

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
NCT05357989Phase 3

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4